Letter | Published:

PtdIns(4,5)P2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling

Naturevolume 559pages423427 (2018) | Download Citation

Abstract

G-protein-coupled receptors (GPCRs) are involved in many physiological processes and are therefore key drug targets1. Although detailed structural information is available for GPCRs, the effects of lipids on the receptors, and on downstream coupling of GPCRs to G proteins are largely unknown. Here we use native mass spectrometry to identify endogenous lipids bound to three class A GPCRs. We observed preferential binding of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) over related lipids and confirm that the intracellular surface of the receptors contain hotspots for PtdIns(4,5)P2 binding. Endogenous lipids were also observed bound directly to the trimeric Gαsβγ protein complex of the adenosine A2A receptor (A2AR) in the gas phase. Using engineered Gα subunits (mini-Gαs, mini-Gαi and mini-Gα12)2, we demonstrate that the complex of mini-Gαs with the β1 adrenergic receptor (β1AR) is stabilized by the binding of two PtdIns(4,5)P2 molecules. By contrast, PtdIns(4,5)P2 does not stabilize coupling between β1AR and other Gα subunits (mini-Gαi or mini-Gα12) or a high-affinity nanobody. Other endogenous lipids that bind to these receptors have no effect on coupling, highlighting the specificity of PtdIns(4,5)P2. Calculations of potential of mean force and increased GTP turnover by the activated neurotensin receptor when coupled to trimeric Gαiβγ complex in the presence of PtdIns(4,5)P2 provide further evidence for a specific effect of PtdIns(4,5)P2 on coupling. We identify key residues on cognate Gα subunits through which PtdIns(4,5)P2 forms bridging interactions with basic residues on class A GPCRs. These modulating effects of lipids on receptors suggest consequences for understanding function, G-protein selectivity and drug targeting of class A GPCRs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).

  2. 2.

    Nehmé, R. et al. Mini-G proteins: Novel tools for studying GPCRs in their active conformation. PLoS One 12, e0175642 (2017).

  3. 3.

    Zocher, M., Zhang, C., Rasmussen, S. G., Kobilka, B. K. & Muller, D. J. Cholesterol increases kinetic, energetic, and mechanical stability of the human β2-adrenergic receptor. Proc. Natl Acad. Sci. USA 109, E3463–E3472 (2012).

  4. 4.

    Dawaliby, R. et al. Allosteric regulation of G protein-coupled receptor activity by phospholipids. Nat. Chem. Biol. 12, 35–39 (2016).

  5. 5.

    Gault, J. et al. High-resolution mass spectrometry of small molecules bound to membrane proteins. Nat. Methods 13, 333–336 (2016).

  6. 6.

    Yen, H. Y. et al. Ligand binding to a G protein-coupled receptor captured in a mass spectrometer. Sci. Adv. 3, e1701016 (2017).

  7. 7.

    Egloff, P. et al. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli. Proc. Natl Acad. Sci. USA 111, E655–E662 (2014).

  8. 8.

    Inagaki, S., Ghirlando, R. & Grisshammer, R. Biophysical characterization of membrane proteins in nanodiscs. Methods 59, 287–300 (2013).

  9. 9.

    Hedger, G. & Sansom, M. S. P. Lipid interaction sites on channels, transporters and receptors: Recent insights from molecular dynamics simulations. BBA-Biomembranes 1858, 2390–2400, (2016).

  10. 10.

    Schlinkmann, K. M. et al. Critical features for biosynthesis, stability, and functionality of a G protein-coupled receptor uncovered by all-versus-all mutations. Proc. Natl Acad. Sci. USA 109, 9810–9815 (2012).

  11. 11.

    Carpenter, B., Nehmé, R., Warne, T., Leslie, A. G. W. & Tate, C. G. Structure of the adenosine A2A receptor bound to an engineered G protein. Nature 536, 104–107 (2016).

  12. 12.

    Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011).

  13. 13.

    Hansen, S. B., Tao, X. & MacKinnon, R. Structural basis of PIP2 activation of the classical inward rectifier K+ channel Kir2.2. Nature 477, 495–498 (2011).

  14. 14.

    Roux, B. The calculation of the potential of mean force using computer simulations. Comput. Phys. Commun. 91, 275–282 (1995).

  15. 15.

    Domański, J., Hedger, G., Best, R. B., Stansfeld, P. J. & Sansom, M. S. P. Convergence and sampling in determining free energy landscapes for membrane protein association. J. Phys. Chem. B 121, 3364–3375 (2017).

  16. 16.

    Roth, C. B., Hanson, M. A. & Stevens, R. C. Stabilization of the human β2-adrenergic receptor TM4–TM3–TM5 helix interface by mutagenesis of Glu1223.41, a critical residue in GPCR structure. J. Mol. Biol. 376, 1305–1319 (2008).

  17. 17.

    Che, T. et al. Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell 172, 55–67 e15, (2018).

  18. 18.

    Miller-Gallacher, J. L. et al. The 2.1 Å resolution structure of cyanopindolol-bound β1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor. PLoS One 9, e92727 (2014).

  19. 19.

    Injin, B. & Hee-Jung, C. Structural features of β2 adrenergic receptor: crystal structures and beyond. Mol. Cells 38, 105–111 (2015).

  20. 20.

    Venkatakrishnan, A. J. et al. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. Nature 536, 484–487 (2016).

  21. 21.

    Zheng, Y. et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540, 458–461 (2016).

  22. 22.

    Liu, X. et al. Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure. Nature 548, 480–484 (2017).

  23. 23.

    Gavi, S., Shumay, E., Wang, H. Y. & Malbon, C. C. G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol. Metab. 17, 48–54 (2006).

  24. 24.

    Scott, D. J., Kummer, L., Egloff, P., Bathgate, R. A. D. & Plückthun, A. Improving the apo-state detergent stability of NTS1 with CHESS for pharmacological and structural studies. BBA-Biomembranes 1838, 2817–2824, (2014).

  25. 25.

    Carpenter, B. & Tate, C. G. Engineering a minimal G protein to facilitate crystallisation of G protein-coupled receptors in their active conformation. Protein Eng. Des. Sel. 29, 583–594 (2016).

  26. 26.

    Warne, T. et al. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454, 486–491 (2008).

  27. 27.

    Warne, T. et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature 469, 241–244 (2011).

  28. 28.

    Warne, T., Serrano-Vega, M. J., Tate, C. G. & Schertler, G. F. Development and crystallization of a minimal thermostabilised G protein-coupled receptor. Protein Expr. Purif. 65, 204–213 (2009).

  29. 29.

    Warne, T., Chirnside, J. & Schertler, G. F. Expression and purification of truncated, non-glycosylated turkey beta-adrenergic receptors for crystallization. Biochim. Biophys. Acta 1610, 133–140 (2003).

  30. 30.

    Carpenter, B. & Tate, C. G. Expression and Purification of Mini G Proteins from Escherichia coli. Bio Protoc. 7, (2017).

  31. 31.

    Ring, A. M. et al. Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature 502, 575–579 (2013).

  32. 32.

    Hillenbrand, M., Schori, C., Schoppe, J. & Pluckthun, A. Comprehensive analysis of heterotrimeric G-protein complex diversity and their interactions with GPCRs in solution. Proc. Natl Acad. Sci. USA 112, E1181–E1190 (2015).

  33. 33.

    Laganowsky, A., Reading, E., Hopper, J. T. S. & Robinson, C. V. Mass spectrometry of intact membrane protein complexes. Nat. Protocols 8, 639–651 (2013).

  34. 34.

    Chen, P. S., Toribara, T. Y. & Warner, H. Microdetermination of phosphorus. Anal. Chem. 28, 1756–1758 (1956).

  35. 35.

    Marty, M. T. et al. Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal. Chem. 87, 4370–4376 (2015).

  36. 36.

    Bird, S. S., Marur, V. R., Sniatynski, M. J., Greenberg, H. K. & Kristal, B. S. Lipidomics profiling by high resolution LC–MS and HCD fragmentation: focus on characterization of mitochondrial cardiolipins and monolysocardiolipins. Anal. Chem. 83, 940–949 (2011).

  37. 37.

    Bechara, C. et al. A subset of annular lipids is linked to the flippase activity of an ABC transporter. Nat. Chem. 7, 255–262 (2015).

  38. 38.

    Egloff, P., Deluigi, M., Heine, P., Balada, S. & Pluckthun, A. A cleavable ligand column for the rapid isolation of large quantities of homogeneous and functional neurotensin receptor 1 variants from E. coli. Protein Expr. Purif. 108, 106–114 (2015).

  39. 39.

    Sobott, F., Hernández, H., McCammon, M. G., Tito, M. A. & Robinson, C. V. A tandem mass spectrometer for improved transmission and analysis of large macromolecular assemblies. Anal. Chem. 74, 1402–1407 (2002).

  40. 40.

    Šali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).

  41. 41.

    Hess, B., Kutzner, C., van der Spoel, D. & Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435–447 (2008).

  42. 42.

    de Jong, D. H. et al. Improved parameters for the Martini coarse-grained protein force field. J. Chem. Theory Comput. 9, 687–697 (2013).

  43. 43.

    Koldsø, H., Shorthouse, D., Hélie, J. & Sansom, M. S. P. Lipid clustering correlates with membrane curvature as revealed by molecular simulations of complex lipid bilayers. PLOS Comput. Biol. 10, e1003911 (2014).

  44. 44.

    Periole, X., Cavalli, M., Marrink, S. J. & Ceruso, M. A. Combining an elastic network with a coarse-grained molecular force field: structure, dynamics, and intermolecular recognition. J. Chem. Theory Comput. 5, 2531–2543 (2009).

  45. 45.

    Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684–3690 (1984).

  46. 46.

    Tironi, I. G., Sperb, R., Smith, P. E. & van Gunsteren, W. F. A generalized reaction field method for molecular dynamics simulations. J. Chem. Phys. 102, 5451–5459 (1995).

  47. 47.

    Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463–1472 (1997).

  48. 48.

    Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38 (1996).

  49. 49.

    Hedger, G., Sansom, M. S. P. & Koldsø, H. The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids. Sci. Rep. 5, 9198 (2015).

  50. 50.

    Hedger, G., Shorthouse, D., Koldso, H. & Sansom, M. S. Free energy landscape of lipid interactions with regulatory binding sites on the transmembrane domain of the EGF receptor. J. Phys. Chem. B 120, 8154–8163 (2016).

  51. 51.

    Hub, J. S., de Groot, B. L. & van der Spoel, D. g_wham—A free weighted histogram analysis implementation including robust error and autocorrelation estimates. J. Chem. Theory Comput. 6, 3713–3720 (2010).

  52. 52.

    Notredame, C., Higgins, D. G. & Heringa, J. T-coffee: a novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 302, 205–217 (2000).

  53. 53.

    Bond, C. S. & Schuttelkopf, A. W. ALINE: a WYSIWYG protein-sequence alignment editor for publication-quality alignments. Acta Crystallogr. D 65, 510–512 (2009).

Download references

Acknowledgements

C.V.R. acknowledges an ERC Advanced Grant ENABLE (641317), an MRC Programme Grant (G1000819) and a Wellcome Trust Investigator Award (104633/Z/14/Z). Further support was provided by the MRC (G.H.), the Royal Society Newton International Fellowship (W.S.), and the BBSRC (M.S.P.S.; BB/L002558/1) and the Wellcome Trust (M.S.P.S.; 092970/Z/10/Z). This work used the ARCHER UK National Supercomputing Service (http://www.archer.ac.uk), supported by EPSRC. A.P. was funded by the Schweizerischer Nationalfonds Grant (31003A_153143). C.G.T. acknowledges the MRC (MC_U105197215), an ERC Advanced Grant EMPSI (339995) and funding from Heptares Therapeutics. We thank M. Hillenbrand for providing Sf9 cells.

Reviewer information

Nature thanks A. Lee, C. Reynolds, J. Whitelegge and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

Author notes

    • Byron Carpenter

    Present address: Warwick Integrative Synthetic Biology Centre, School of Life Sciences, The University of Warwick, Coventry, UK

Affiliations

  1. Chemical Research Laboratory, University of Oxford, Oxford, UK

    • Hsin-Yung Yen
    • , Kin Kuan Hoi
    • , Idlir Liko
    • , Di Wu
    •  & Carol V. Robinson
  2. OMass Technologies, Kidlington, UK

    • Hsin-Yung Yen
    •  & Idlir Liko
  3. Department of Biochemistry, University of Oxford, Oxford, UK

    • George Hedger
    • , Michael R. Horrell
    • , Wanling Song
    •  & Mark S. P. Sansom
  4. Biochemisches Institut, Universität Zürich, Zurich, Switzerland

    • Philipp Heine
    •  & Andreas Plückthun
  5. MRC Laboratory of Molecular Biology, Cambridge, UK

    • Tony Warne
    • , Yang Lee
    • , Byron Carpenter
    •  & Christopher G. Tate

Authors

  1. Search for Hsin-Yung Yen in:

  2. Search for Kin Kuan Hoi in:

  3. Search for Idlir Liko in:

  4. Search for George Hedger in:

  5. Search for Michael R. Horrell in:

  6. Search for Wanling Song in:

  7. Search for Di Wu in:

  8. Search for Philipp Heine in:

  9. Search for Tony Warne in:

  10. Search for Yang Lee in:

  11. Search for Byron Carpenter in:

  12. Search for Andreas Plückthun in:

  13. Search for Christopher G. Tate in:

  14. Search for Mark S. P. Sansom in:

  15. Search for Carol V. Robinson in:

Contributions

H.-Y.Y., K.K.H. and I.L. performed all mass spectrometry experiments on the GPCR, mini-GS and nanobody. D.W. performed lipidomics. G.H., M.R.H., W.S., and M.S.P.S. performed molecular dynamics simulations and analyses. P.H. purified the NTSR1 receptor in the apo state. T.W. purified β1AR, Y.L. purified A2AR and B.C. purified mini-GS. A.P., C.G.T., M.S.P.S. and C.V.R supervised the research and H.-Y.Y. and C.V.R. wrote the paper with contributions from all authors.

Competing interests

H.-Y.Y. and I.L. are founders and employees of OMass Technologies. C.V.R is a founder of and consultant for OMass Technologies.

Corresponding authors

Correspondence to Mark S. P. Sansom or Carol V. Robinson.

Extended data figures and tables

  1. Extended Data Fig. 1 Identification of lipids bound to NTSR1(HTGH4-ΔIC3B).

    a, Endogenous lipids bound to NTSR1(HTGH4-ΔIC3B), isolated from E. coli, are identified as PA following m/z selection in the mass spectrometry quadrupole of the NTSR1:lipid 11+ charge state (highlighted yellow) and collisional activation to dissociate PA and its homologues (m/z, 700–760 Da). b, Lipidomics analysis of purified NTSR1 with three technical replicates reveals peaks at low m/z. MS/MS spectra of the precursor ion (M-H-1) at m/z 699.32 highlighted yellow, leads to definitive fragment ions at m/z 281 and 417 consistent with the structure of PA (36:2). c, Analogous lipidomics analysis of purified β1AR from insect cells with three technical replicates. MS/MS spectra of the two [M-H-1] precursor ions (m/z 758.50 and 786.53) identified the lipids as PS (34:2) and PS (36:2) respectively with diagnostic fragments indicated.

  2. Extended Data Fig. 2 Lipid-binding preference of NTSR1 and β1AR.

    ae, The binding of NTSR1(HTGH4-ΔIC3B), measured by mass spectrometry (n = 3 independent experiments), to the phospholipids PA (a), PS (b), PI (c), PC (d) and DAG (e). The measurements were performed at different lipid concentrations (0 to 160 µM) and the percentages of individual lipid-binding peaks (sum of apo protein and all lipid adducts obtained in the region of the mass spectrum under study) were plotted against lipid concentrations in solution. The lipid-binding curves were deduced from fitting to one-site total binding. Values of s.d. were calculated from three independent replicate experiments at each concentration. The results show that NTSR1 interacts preferentially with anionic phospholipids (PA and PS), as no binding was observed for neutral (DAG) and zwitterionic (PC) lipids. f, g, Exogenous POPS (f) and PtdIns(4)P (g) were added to β1AR at different final concentrations (10 µM is shown here). Spectra were recorded for a range of lipid concentrations from 0 to 80 µM for PS and 0 to 20 µM for PtdIns(4)P. Peak intensities of the individual PtdIns(4)P-bound species were measured and plotted against lipid concentration to yield a relative affinity for one PtdIns(4)P binding (1×), two PtdIns(4)P molecules binding (2×) or three PtdIns(4)P molecules binding (3×); only the first PtdIns(4)P molecule binds with high affinity (see Fig. 1a). Data are mean ± s.d. from three independent experiments. Source data

  3. Extended Data Fig. 3 Investigation of the phospholipid preferences of A2AR and NTSR1.

    a, A representative mass spectrum of purified A2AR from three independent experiments revealed truncations of the N-terminal sequence (MPIM). The arrows between species indicate the mass differences corresponding to truncated amino acids (M, PI and M). b, A competitive binding assay (n = 3 independent experiments) in which A2AR was incubated with a mixture of lipids (PI, PtdIns(4)P, PI(4,5)P2, and PtdIns(3,4,5)P3) before mass spectrometry, indicated that PtdIns(4,5)P2 binds with a higher affinity than the other phospholipids to A2AR. c, The analogous competitive binding assay, in which NTSR1 was incubated with a mixture of lipids (PI, PtdIns(4)P, PI(4,5)P2 and PtdIns(3,4,5)P3) before mass spectrometry. Ratio to apo is plotted as a function of concentration and defined as the ratio of the intensity corresponding to individual PI phosphate adducts to the receptor in the apo state (inset). The same data analysis methods are used for Fig. 1b. PtdIns(4,5)P2 binds with a higher affinity than the other phospholipids to A2AR. Data are shown as mean ± s.d. from three independent replicates. d, A representative mass spectrum of A2AR (n = 3 independent experiments) used for preparation of the G-protein complex reveals lower abundance of PS and PI adducts prior to coupling to G proteins. Source data

  4. Extended Data Fig. 4 NTSR1–PtdIns(4,5)P2 and β1AR–PtdIns(4,5)P2 interactions within CGMD simulations, and comparison of PtdIns(4,5)P2 contacts among different GPCRs.

    a, Volumetric density surfaces showing the average spatial occupancy of PtdIns(4,5)P2 lipids around a crystal structure of NTSR1(TM86V-ΔIC3B) (PDB: 4BUO), which shares a greater sequence identity to the wild-type receptor (91%) than NTSR1(HTGH4-ΔIC3B) (86%), contoured to show the major PtdIns(4,5)P2-interaction sites. Density surfaces were calculated over 5 μs of CGMD (blue surface, n = 10 independent experiments), and 100 μs of CGMD (magenta, n = 1 experiment). The cytoplasmic side of NTSR1 structure is coloured from white (low PtdIns(4,5)P2 interaction) to red (high PtdIns(4,5)P2 interaction). Extending a simulation to 100 µs revealed no overall change in the patterns of PtdIns(4,5)P2 interaction. Less specific, and hence more dynamic, interaction was seen for the acyl chain moieties of PtdIns(4,5)P2, which yielded more diffuse probability densities. b, β1AR–PtdIns(4,5)P2 interactions within CGMD simulations. Contact patterns are shown for simulations containing 5% PtdIns(4,5)P2 in the lipid bilayer and thermostable β1AR (PDB: 2Y03, top), 10% PtdIns(4,5)P2 and thermostable β1AR (middle), and 10% PtdIns(4,5)P2 and β1AR(S68R) construct (bottom). In each case PtdIns(4,5)P2 contacts were calculated over 5 μs of CGMD (n = 10 independent experiments; error bars, s.d.), with each repeat simulation initiated from different random system configurations. c, PS and PtdIns(4,5)P2 contacts with NTSR1 as a function of residue position, for PC:PS membranes (top left), PC:PS:PtdIns(4,5)P2 membranes (top right), PC:PtdIns(4,5)P2 membrane (bottom left) and PC:PS:PtdIns(4,5)P2 (bottom right). The position of helices is denoted by horizontal grey bars. Lipid contact is calculated as the mean number of contacts between each residue and a given lipid species per frame, using a 6 Å distance cut-off. n = 3; error bars, s.d.. d, PtdIns(4,5)P2 contacts seen in CGMD simulations for nine class A GPCRs: histamine H1 receptor, PDB 3RZE; β1 adrenergic receptor, 2VT4; β2 adrenergic receptor, 2RH1; CB1 cannabinoid receptor, 5TGZ; M4 muscarinic acetylcholine receptor, 5DSG; adenosine A2A receptor, 3EML; dopamine D3 receptor, 3PBL; sphingosine 1-phosphate receptor, 3V2W; rhodopsin, 1F88. GPCR sequences are shown, with TM helices, intracellular loops (ICL) and H8 helices indicated by horizontal bars, and with amino acids coloured according to the mean number of contacts per simulation frame with the PtdIns(4,5)P2 molecules. Green boxes correspond to the high frequency of PtdIns(4,5)P2 interactions discussed in the main text for the TM1, TM4, and TM7/H8 motifs of NTSR1. Contacts were computed over 1 μs CGMD simulations (n = 3 independent experiments) for each GPCR, using a 6 Å cut-off. Sequences were aligned using T-Coffee52 and mapping of protein–lipid contact data onto the sequence alignment used ALINE53.

  5. Extended Data Fig. 5 Site-directed mutagenesis attenuates PtdIns(4,5)P2 binding to NSTR1.

    a, Schematic representation of the experimental protocol designed to combine mass spectrometry with mutagenesis to produce mutants of lower molecular mass than wild type, which, when incubated with PtdIns(4,5)P2, yield a direct readout of the effect of mutations in specific regions. b, PtdIns(4,5)P2 binding of NTSR1 mutants on residues that exhibit the highest frequency of PtdIns(4,5)P2 interaction in molecular dynamics simulation. Mutation of NTSR1(HTGH4-ΔIC3B) residues on TM1 (R46G, K47G and K48G (R43G, K44G and K45G in NTSR1(TM86-ΔIC3B); R91G, K92G, K93G in wild type)), TM4 (R138I, R140T, K142L and K143L (R135I, R137T, K139L and K140L in NTSR1(TM86-ΔIC3B); R183I, R185T, K187L and K188L in wild type)) and TM7-H8 (R316N (R311N in NTSR1(TM86-ΔIC3B); R377N in wild type)) attenuate PtdIns(4,5)P2 binding, and indicate that the TM4 interface is a preferential binding site over TM1 and TM7-H8 interfaces. Selection of residues for mutations was guided by molecular dynamics (Extended Data Fig. 4) and previous studies in which binding of a fluorescently labelled agonist, BODIPY neurotensin, to NTSR1, was screened and used to monitor efficient production, insertion, and folding10.

  6. Extended Data Fig. 6 PtdIns(4,5)P2 binds preferentially to β1AR in an active state and stabilizes β1AR coupled to mini-Gs and A2AR-mini-Gs complex.

    a, A time-course experiment was performed to monitor the formation of active β1AR–mini-Gs complex. The coupling efficiency (percentage) was calculated from the relative intensity of peaks assigned to β1AR–mini-Gs coupling in the appropriate lipid-bound state. The plot indicates that mini-Gs coupling is enhanced by PtdIns(4,5)P2 when more than two lipid molecules are bound to the receptor. Error bars represent s.d. from at least three independent experiments. b, Plot of PMF for the interaction of mini-Gs with A2AR in the presence of PtdIns(4,5)P2 (green) or PS (grey). The PMF is calculated along a reaction coordinate (Δz) corresponding to the centre–centre separation of the mini-Gs and receptor proteins along the z axis (normal to the bilayer plane). The interaction of mini-Gs with the A2AR is stabilized in the presence of PtdIns(4,5)P2 by 50 ± 10 kJ mol−1 relative to PS. Error bars (which are <10 kJ mol−1) are from bootstrap sampling of the PMFs and therefore represent the ‘statistical’ errors in estimating the well depth from a given set of simulations and PMF calculation (n = 3 independent experiments). We therefore estimate a minimum error of ≤10 kJ mol−1. c, Mass spectra were recorded for a 1:1 equimolar mix of an inactive unliganded β1AR variant, E130W, and its unmodified active counterpart (co-purified with the agonist isoprenaline) in the presence of PI(4,5)P2. Lipid binding occurred on both receptors, but following normalization to account for differences in ionization efficiency, a clear preference for PtdIns(4,5)P2 binding to the active receptor was observed. Bars represent mean ± s.d. Source data

  7. Extended Data Fig. 7 Detection of nanobody coupling to β1AR.

    Peaks in the mass spectrum assigned to Nb6B9 binding to β1AR to form an equimolar β1AR–Nb6B9 complex are highlighted in orange, and demonstrate complete complex formation, implying that nanobody has a higher affinity than mini-Gs for β1AR. n = 3 independent experiments.

  8. Extended Data Fig. 8 Structural comparison of class A and class B GPCRs in complex with trimeric Gαβγ complexes.

    The PtdIns(4,5)P2 contacts of the Gαs subunit observed in molecular dynamics simulations (green spheres) are highlighted on the structures of trimeric G-protein interactions with β2AR (PDB: 3SN6), the glucagon-like peptide-1 receptor (GLP-1) (PDB: 5VAI) and the calcitonin receptor (CTR) (PDB: 5UZ7). Basic residues on the interface adjacent to the cytoplasmic end of TM4 are highlighted as purple spheres. Lower panels show an expanded view, highlighting the conserved pattern of PtdIns(4,5)P2 bridging in class A GPCRs (β2AR and A2AR (Fig. 3e)), both of which have basic residues on TM4 (Lys140 and Arg107/111) that are not present in the class B GPCRs GLP-1R and CTR.

  9. Extended Data Table 1 Lipidomics analysis of purified β1AR
  10. Extended Data Table 2 Simulations run

Supplementary information

  1. Supplementary Information

    This file contains Supplementary Notes and References

  2. Reporting Summary

Source data

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41586-018-0325-6

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.